Question 1

How much GHK-Cu should be taken, and how often?

Accepted Answer

No study among the research behind this page has established an amount of GHK-Cu (copper tripeptide-1) for a person, by any route, at any frequency. A 2026 orthopaedic review that examined the compound alongside five others concludes that information regarding the indications, dosing, frequency, and duration of treatment remains unknown. That is the state of the record, and it is worth being specific about why. The published work on GHK-Cu is mostly laboratory and animal research, and the animal experiments report quantities per kilogram of the animal rather than quantities for a person. The human work that exists is cosmetic and small, and it measured outcomes rather than searching for an amount. So the question has not been answered badly. It has not been asked of a study designed to answer it, which is a different situation and a more useful one to know about.

Question 2

What amounts of GHK-Cu have been used in animal studies?

Accepted Answer

Two animal studies print a figure, and the two figures are nearly two orders of magnitude apart. In an Alzheimer's model, male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age. A separate experiment in mice exposed to cigarette smoke administered considerably less. There, GHK-Cu treatment (0.2 and 2 mg/kg) reduced smoke-induced muscle mass loss in those mice, and the investigators ran two quantities precisely because the appropriate one was not established. Hold those side by side: 15 mg/kg administered into the nose three times weekly, against 0.2 and 2 mg/kg in an entirely different category of experiment. The distance between them is not a disagreement between investigators. It is two groups interrogating two organs by two routes, and neither was searching for a figure that would transfer to a person. Per-kilogram scaling from a mouse to a human being is not validated for this compound, and we do not publish that conversion.

Question 3

How often was GHK-Cu given in the published studies?

Accepted Answer

Three times a week is the only frequency stated in a long animal course. The Alzheimer's experiment gave it intranasally 3 times per week for 3 months, which is a schedule chosen by investigators rather than one established by comparison against other schedules. Nothing among the research behind this page compares one frequency against another in GHK-Cu research, so there is no basis for daily, weekly or anything between. The nearest the literature comes is a formulation designed to need fewer administrations. An injectable filler loaded with the compound exhibits sustained release properties for 7 days, which the authors say reduces injection frequency. Read what that implies rather than what it promises. Engineering a carrier to release the compound over a week is an admission that the compound does not persist on its own, and it says nothing about how often a plain solution would need to be given.

Question 4

What routes has GHK-Cu been given by?

Accepted Answer

Four appear in the published record, and they are not interchangeable. Into the nose is the route of the longest animal course, where the compound was given intranasally three times weekly for three months. Into the skin is the cosmetic route, and onto the skin as a gel is the route of the only registered trial, Topical GHK-Cu Gel for Acute Skin Wound Healing. Into a tissue defect is the fourth, and it arrives inside a device rather than a syringe of solution. In a rabbit fascia model, GHK-Cu serves as a stable copper source to provide a sustained release of Cu ions for cellular uptake within an engineered delivery system. Each route was selected for the organ under investigation, and no study among the research behind this page has compared any two of them against one another. A quantity that carries meaning by one route carries none by another, which is precisely why the route belongs inside any sentence containing a number.

Question 5

How much GHK-Cu actually crosses the skin from a topical amount?

Accepted Answer

Almost none of it, if the skin is intact, and this is the single most important number on the page for anyone applying it. A 2015 study measured permeation across human skin in the laboratory. Over 9 hours, 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper crossed human skin that had been treated with microneedles, whereas almost no peptide or copper got through intact human skin. The reason is chemical rather than incidental. A 2025 review states that GHK-Cu is a fairly hydrophilic compound with limited permeation through the lipophilic stratum corneum, which is the waxy outer layer of skin that water-loving molecules struggle to cross. So a percentage on a jar describes what was mixed rather than what arrives. The gap between the two has been measured once, in a laboratory, on skin that was deliberately punctured first. That is a measurement of a delivery method rather than a dose.

Question 6

Do delivery systems change how much GHK-Cu is needed?

Accepted Answer

They change how much arrives, which is a different number from how much is applied. A 2026 study tested tiny particles that puncture the skin, and copper tripeptide-1 was one of the compounds they carried. The work was done in porcine skin ex vivo, meaning pig skin in the laboratory, and skin treatment with polymer STAR particles increased intradermal drug delivery by up to 37-fold. A 37-fold difference swamps any adjustment somebody might make to the amount printed on a label. It also means that two preparations carrying identical milligram figures are not delivering identical quantities into skin. That is where the GHK-Cu dosing question actually sits. A 2025 review notes that the transport of liposomes containing GHK-Cu received little attention, so even the carriers used most in cosmetics have not been measured for what they deliver. Until that is measured, a stated amount is an input with an unknown output rather than a dose.

Question 7

What concentrations of GHK-Cu appear in formulation studies?

Accepted Answer

Formulation papers print concentrations rather than doses, and the distinction matters because a concentration is a property of a liquid while a dose is an amount that reaches somebody. A 2023 liposome study settled on carriers hydrated with 0.5 mg/cm3 GHK-Cu, achieving an encapsulation efficiency of 31.7 ± 0.9%, meaning roughly two-thirds of the peptide never made it inside the carrier at all. That figure is a laboratory result from one preparation method, and it is not a property of GHK-Cu in general. Change the lipid, the hydration step or the peptide concentration and the proportion captured changes with it. For a reader holding a product, the useful implication is narrow but real. A concentration on a label describes the mixture, an encapsulation figure describes how much of it is inside a carrier, and neither of them describes what reaches the tissue underneath.

Question 8

How much GHK is already in the body?

Accepted Answer

This is the comparison that makes milligram figures look strange, and it is specific to GHK-Cu because the molecule occurs naturally in human blood. A 2020 review reports that GHK is a naturally occurring peptide found in human serum with levels averaging 200 ng/ml at age 20 but declining to an average of 80 ng/ml by age 60. Nanograms per millilitre is a billionth of a gram in a thousandth of a litre. A vial labelled in milligrams is working in units millions of times larger than the circulating concentration the body maintains for itself. The decline is measurable in illness as well as in ageing. In one study, plasma GHK levels were decreased in patients with COPD, at 70.27 ± 38.87 ng/mL against 133.0 ± 54.54 ng/mL in healthy controls. No study among the research behind this page has published what quantity, by what route, would restore a circulating level, which is the study that would connect a vial to the body's own arithmetic.

Question 9

Is there a published amount for injected GHK-Cu?

Accepted Answer

No published human study has injected GHK-Cu and reported an amount. In people it appears as a gel applied to the skin, or as a measurement in a blood sample. The injection research is entirely in animals, and most of it sits inside a device rather than a plain syringe. Where a figure is printed for an injected form, it belongs to the carrier. One study loaded GHK-Cu onto HAPs by electrostatic adsorption, where HAPs are tiny mineral spheres used in fillers, and then watched it come off over a week. The numbers that follow describe a material rather than a schedule. A 2026 review of six peptides, GHK-Cu among them, found that significant heterogeneity existed in dosing and route of administration. That spread is the honest answer to an injection question. The published amounts differ because unrelated experiments produced them, rather than because anyone has closed in on a figure.

Question 10

How much bacteriostatic water goes into a 100 mg GHK-Cu vial?

Accepted Answer

That is arithmetic and it has an exact answer. A 100 mg vial contains 100,000 micrograms, so 1 mL of bacteriostatic water produces 100,000 mcg/mL, 2 mL produces 50,000 mcg/mL, 5 mL produces 20,000 mcg/mL and 10 mL produces 10,000 mcg/mL. On a U-100 insulin syringe each unit mark is one hundredth of a millilitre. At 20,000 mcg/mL a single mark therefore holds 200 micrograms, and ten marks hold 2 milligrams. Those conversions are fixed and they can be checked by hand. What the arithmetic cannot supply is the number to aim at, and the scale is worth noticing before any calculation is done. The body's own circulating concentration is measured in nanograms per millilitre, while the vial is labelled in hundreds of milligrams, and no study among the research behind this page connects the two. The arithmetic tells a reader what a millilitre contains rather than what a body would need. Our reconstitution calculator runs these sums on figures you enter and proposes no target.

Question 11

Does GHK-Cu dosing differ from plain GHK?

Accepted Answer

They are not the same material, and the copper is the reason. A 2012 review notes that GHK has high affinity for copper ions and easily forms a copper complex or GHK-Cu, so a quantity of the peptide and a quantity of the complex are not describing identical contents. That difference carries into every measurement. In the skin permeation work, peptide and copper were counted separately, and 134 ± 12 nanomoles of peptide crossed alongside 705 ± 84 nanomoles of copper, which is roughly five copper ions for every peptide molecule that made it through. Those numbers do not move together, so a milligram figure on a label does not settle how much peptide and how much copper arrive. Anyone comparing two preparations by their stated amount is comparing two things that were never shown to contain the same ratio of the two components.

Question 12

What are the registered GHK-Cu trials testing?

Accepted Answer

Two are currently listed, and neither of them is a dose-finding investigation. The first is Topical GHK-Cu Gel for Acute Skin Wound Healing, a phase 2 study that is RECRUITING and has published no results whatsoever. The second is not an intervention trial at all. It is a Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults, listed as NOT_YET_RECRUITING, and its outcome is a blood concentration rather than a clinical endpoint. Those two registrations constitute the entire forward-looking record, and between them they will produce a wound outcome from a gel and a circulating concentration from a patch. Neither is constructed to compare quantities against one another, so neither will deliver a schedule when it eventually reports. A registration is a plan rather than a result, and the plans on file do not include establishing an amount.

Question 13

Why do the published GHK-Cu amounts vary so much?

Accepted Answer

Because they were produced by experiments with nothing in common except the molecule. One gave 15 mg/kg into the nose of a mouse for three months. Another gave 0.2 and 2 mg/kg to mice breathing cigarette smoke. A third worked at 0.5 mg/cm3 inside a liposome on a laboratory bench. Those are three fundamentally different categories of question. None of them was investigating what quantity suits a person, and a figure lifted out of any of them arrives stripped of the organ, the route and the animal that originally gave it meaning. The structural reason underneath is that nothing has been approved. A 2026 review of GHK-Cu and five other peptides reports that no clinical data support its use for musculoskeletal conditions, and the same review finds dosing, frequency and duration unknown across the group. Without a regulator's figure to sit near, every published amount is just the amount that one experiment happened to use.

Question 14

What did the human GHK measurements actually measure?

Accepted Answer

They measured what was already circulating, not what anybody was given. A 2023 study found that the plasma GHK levels of patients with asthma were significantly lower than those of age-matched healthy controls, and a separate study found the same pattern in people with COPD. Both of those are observations of a natural level in illness. Neither administered GHK-Cu to a person, and neither reports an amount, because measuring a concentration and giving a quantity are different questions. The step from one to the other has only been taken in animals. In the asthma work, the follow-up was done in ovalbumin-induced mice of asthma model treated with PBS or GHK-Cu, with no human arm. So the human side of the GHK-Cu literature establishes that the molecule declines in disease, rather than what any administered quantity would do about that decline.

Experiment	Animals	Amount studied	Route and schedule
Alzheimer's model	5xFAD transgenic mice, from 4 to 7 months of age	15 mg/kg	Into the nose, 3 times per week for 3 months
Cigarette-smoke experiment	Mice exposed to cigarette smoke	0.2 and 2 mg/kg	Not stated in the summary

GHK-Cu protocols in the published literature